Fresenius Kabi And Formycon Ally On Stelara Rival
German Firms Strike Global Licensing Agreement For FYB202 Ustekinumab Biosimilar
Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.
